NCT05286957 - MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

NSCLC

Interventions

DRUG

adjuvant tislelizumab and chemotherapy for MRD+ patients

"MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)"

DRUG

adjuvant tislelizumab and chemotherapy for MRD+ patients

patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status

DRUG

adjuvant chemotherapy for MRD- patients

MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles

Trial Locations (1)

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University,, Zhengzhou